Oral Smegglutinin: A multifaceted innovator in reshaping metabolic health
Share
A small pill carries four missions: lowering blood sugar, reducing weight, protecting the heart, and protecting the liver. It is quietly reshaping the treatment landscape for hundreds of millions of patients with metabolic diseases worldwide . On January 26, 2024, a new chapter in diabetes treatment was opened by an approval from the China National Medical Products Administration (NMPA) – semaglutide tablets, the world's first oral glucagon-like peptide-1 receptor agonist (GLP-1RA), were officially approved for marketing in China. This once-daily oral formulation not only breaks the constraint that GLP-1 drugs must be injected, but also demonstrates multiple benefits that surpass traditional hypoglycemic drugs with a series of impressive clinical data.
Breakthrough Mechanism: A Technological Revolution in a Small Pill
The core breakthrough of oral semaglutide lies in solving the global challenge of oral absorption of peptide drugs. It consists of the semaglutide molecule and the absorption enhancer SNAC . SNAC is an N-acetylated amino acid derivative of salicylic acid, achieving a breakthrough in gastrointestinal absorption through a triple action:
● It locally raises the pH level in the stomach, protecting semaglutide from degradation by pepsin.
● Promotes drug monomerization and enhances its penetration ability
● It inserts into the gastric epithelial cell membrane, altering its fluidity and promoting transcellular drug transport.
This ingenious design makes the bioavailability of oral semaglutide nearly 100 times higher than that of oral administration alone , turning the impossible into a reality for oral peptide drugs.
Pharmacokinetic studies showed that, despite the different routes of administration, oral and injectable formulations achieved comparable blood glucose-lowering, weight-loss, and safety profiles at the same blood drug concentration . A once-daily oral administration of 14 mg semaglutide and a once-weekly subcutaneous injection of 1 mg semaglutide achieved similar blood drug concentrations, demonstrating the same therapeutic effect despite different routes.
Lowering blood sugar and losing weight: the core role of dual metabolic regulation
As a GLP-1 receptor agonist, oral semaglutide improves metabolic health through multiple mechanisms:
● Glucose-dependent hypoglycemic mechanism : It promotes insulin secretion only when blood glucose is elevated, while inhibiting glucagon release, significantly reducing the risk of hypoglycemia.
● Delayed gastric emptying effect : prolongs the time food stays in the stomach, enhancing the feeling of fullness.
● Central appetite suppression : Acts on the hypothalamus feeding center to reduce hunger.
Global PIONEER series clinical trials have confirmed that oral smegglutinin can reduce glycated hemoglobin (HbA1c) by up to 1.5% , with an HbA1c target achievement rate of up to 80%. It can also significantly reduce weight, up to 5.0 kg, and improve blood pressure and blood lipid profile.
The OASIS 2 study, released in 2025, provides even more encouraging data for East Asian populations: In overweight or obese East Asians (BMI ≥ 27 with complications or BMI ≥ 35), daily oral semaglutide treatment for 68 weeks significantly reduced body weight by 13.1 percentage points compared to placebo (14.3% vs 1.3%), with 84.3% of participants achieving their weight loss target of ≥ 5%.
This means that 8 out of every 10 users successfully lost more than 5% of their weight.
Cardiovascular protection: Breakthrough benefits beyond blood sugar reduction
The most notable breakthrough of oral semaglutide lies in its cardiovascular protective effect. The SOUL study, presented at the 2025 ACC meeting , is a landmark trial covering 444 centers in 33 countries, enrolling 9,650 patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).
The study results showed that, compared with placebo, the oral semaglutide group:
● The risk of major adverse cardiovascular events is significantly reduced by 14% (cardiovascular death, non-fatal myocardial infarction, or stroke).
● Reduced risk of non-fatal myocardial infarction by 26%
● The risk of non-fatal stroke is reduced by 12%.
● Reduced risk of cardiovascular death by 7%
This is the first large-scale randomized controlled trial to demonstrate the cardiovascular benefits of oral GLP-1 agonists. Previously, injectable semaglutide had been shown to have cardiovascular benefits, but the SOUL study is the first to demonstrate that oral formulations have equivalent effects, providing an alternative for patients who cannot tolerate injections or have poor adherence.
Another STRIDE trial showed that in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes, semaglutide treatment significantly improved maximum walking distance, with a median improvement of 26.4 meters , while reducing the risk of death due to symptom exacerbation or the need for revascularization treatment by up to 54%.
Liver protection: New hope for the treatment of fatty liver disease
A groundbreaking study published in the *New England Journal of Medicine* in May 2025 revealed the significant efficacy of semaglutide in treating metabolic-associated steatohepatitis (MASH, formerly known as NASH). This trial, which included 1197 patients diagnosed with MASH by biopsy and with stage 2-3 liver fibrosis, showed that:
● In the semaglutide group, 62.9% of patients achieved remission of steatohepatitis and no worsening of fibrosis , compared to only 34.3% in the placebo group.
● 36.8% of patients in the semaglutide group achieved improvement in fibrosis and no worsening of steatohepatitis, compared to only 22.4% in the placebo group.
● The proportion of patients whose steatohepatitis resolved and whose fibrosis improved reached 32.7% , significantly higher than the 16.1% in the placebo group.
● Patients experienced an average weight loss of 10.5%, significantly better than the 2.0% reduction in the placebo group.
These data provide MASH patients with the most promising treatment options in nearly a decade, achieving a triple benefit of " hepatitis improvement, fibrosis stabilization, and weight loss ".
Correct Use: Key Points of Scientific Drug Use
The use of oral semaglutide should follow scientific guidelines:
● Target population : Currently, the approved indication in China is type 2 diabetes; the indication for obesity treatment has not yet been approved.
● Tips for administration : Take with a small amount of water on an empty stomach every morning after waking up . Wait at least 30 minutes before eating, drinking, or taking other medications.
● Dosage adjustment : Start with a dose of 3 mg/day, which can be increased to 7 mg/day after 30 days. If the effect is not satisfactory, the dose can be increased to 14 mg/day.
● Contraindications : Patients with a personal or family history of medullary thyroid carcinoma or type 2 multiple endocrine neoplasia syndrome should not use this product; use with caution in patients with pancreatitis, severe renal insufficiency, and pregnant or lactating women.
The most common adverse reactions were gastrointestinal reactions (incidence 63.4% vs. 34.8% in the placebo group), such as nausea, vomiting, and abdominal distension, but most were transient. No dose adjustment was required for patients with mild to moderate hepatic or renal impairment.
Future Outlook: Possibilities Beyond Metabolic Health
As research progresses, the application prospects of oral smegglutinin are constantly expanding. In addition to its proven metabolic and cardiovascular benefits:
● China is conducting clinical trials targeting weight loss indications and Alzheimer's disease.
● Its kidney-protective effect on patients with chronic kidney disease is under in-depth research.
● Its anti-inflammatory and neuroprotective effects provide new insights into the treatment of neurodegenerative diseases.
The cardiovascular protective mechanism of smegglutinin has also been gradually elucidated, including:
● Direct anti-inflammatory effect: Significantly reduces high-sensitivity C-reactive protein (hs-CRP) levels
● Improves endothelial function: Promotes vasodilation
● Anti-atherosclerosis: Stabilizes vulnerable plaques
Combined with its significant effects on improving weight, blood sugar, blood pressure, and blood lipids, it forms a multi-target cardiovascular protection network.
A revolutionary breakthrough in metabolic health management
The clinical value of oral semaglutide far surpasses that of traditional hypoglycemic drugs, realizing a paradigm shift from "simple blood sugar control" to " comprehensive metabolic management and multi-organ protection ." With the increasing availability of oral formulations, more patients will have the opportunity to access this revolutionary treatment.
The scientific community continues to accelerate its exploration of GLP-1 receptor agonists. In the foreseeable future, this class of drugs is expected to become the cornerstone treatment for metabolic syndrome and its related complications, reshaping our understanding and practice of chronic disease management.
A small pill that is changing the health of hundreds of millions of people around the world is writing a new chapter in medical history.
🏆 Asakusa Cosmetics provides you with
✔️ Authentic Smeglucopyranoside
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
--------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.